Literature DB >> 32647417

Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma.

Arihant Jain1, Ankur Jain2, Pankaj Malhotra1.   

Abstract

Risk-stratification is an essential management tool in defining prognosis of haematological neoplasms, both from patient and physician perspective. We define a new prognostic term "Dynamic Response Assessment Method(s) (DRAM)" as "method(s) used for re-stratifying disease prognosis at fixed intervals during the treatment course". The risk stratification is done after a fixed duration of treatment or chemotherapy cycles using sensitive techniques. The information obtained then can be used for further therapeutic decisions and prognostication. Currently, there is enough evidence that response to treatment improves the prognostic value of baseline disease variables in the management of Chronic Myeloid Leukemia, Hodgkin lymphoma, Diffuse Large B cell Lymphoma, and Multiple Myeloma. Through this review, we discuss the current evidence based application of "DRAM" to guide therapeutic decisions in these malignancies. We also discuss how the results of "DRAM" can be incorporated for redefining prognosis and counselling the patients with these selected hematologic malignancies. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Chronic Myeloid Leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Multiple Myeloma; Prognosis; Risk-stratification

Year:  2019        PMID: 32647417      PMCID: PMC7326854          DOI: 10.1007/s12288-019-01213-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  58 in total

1.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

Authors:  Jun Imagawa; Hideo Tanaka; Masaya Okada; Hirohisa Nakamae; Masayuki Hino; Kazunori Murai; Yoji Ishida; Takashi Kumagai; Seiichi Sato; Kazuteru Ohashi; Hisashi Sakamaki; Hisashi Wakita; Nobuhiko Uoshima; Yasunori Nakagawa; Yosuke Minami; Masahiro Ogasawara; Tomoharu Takeoka; Hiroshi Akasaka; Takahiko Utsumi; Naokuni Uike; Tsutomu Sato; Sachiko Ando; Kensuke Usuki; Satoshi Morita; Junichi Sakamoto; Shinya Kimura
Journal:  Lancet Haematol       Date:  2015-11-10       Impact factor: 18.959

Review 2.  Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Authors:  Tanya M Wildes; Kenneth C Anderson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Authors:  Jacob P Smeltzer; Amanda F Cashen; Qin Zhang; Andrew Homb; Farrokh Dehdashti; Camille N Abboud; John F Dipersio; Keith E Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; Nancy L Bartlett; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-03       Impact factor: 5.742

4.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

5.  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Authors:  Edward A Stadtmauer; Marcelo C Pasquini; Beth Blackwell; Parameswaran Hari; Asad Bashey; Steven Devine; Yvonne Efebera; Siddharta Ganguly; Cristina Gasparetto; Nancy Geller; Mary M Horowitz; John Koreth; Kristin Knust; Heather Landau; Claudio Brunstein; Philip McCarthy; Courtney Nelson; Muzaffar H Qazilbash; Nina Shah; David H Vesole; Ravi Vij; Dan T Vogl; Sergio Giralt; George Somlo; Amrita Krishnan
Journal:  J Clin Oncol       Date:  2019-01-17       Impact factor: 44.544

Review 6.  Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.

Authors:  Craig Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Antonio Palumbo; Francesca Gay; Federica Cavallo; Francesco Di Raimondo; Alessandra Larocca; Izhar Hardan; Arnon Nagler; Maria T Petrucci; Roman Hajek; Sara Pezzatti; Michel Delforge; Francesca Patriarca; Francesca Donato; Chiara Cerrato; Chiara Nozzoli; Zhinuan Yu; Luana Boccadifuoco; Tommaso Caravita; Giulia Benevolo; Tommasina Guglielmelli; Donatella Vincelli; Christian Jacques; Meletios A Dimopoulos; Giovannino Ciccone; Pellegrino Musto; Paolo Corradini; Michele Cavo; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

Review 8.  Minimal residual disease analysis in myeloma - when, why and where.

Authors:  Uday Yanamandra; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2017-10-11

9.  Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors:  O Landgren; S Devlin; M Boulad; S Mailankody
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

10.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

Authors:  Timothy P Hughes; Jeffrey H Lipton; Nelson Spector; Francisco Cervantes; Ricardo Pasquini; Nelma Cristina D Clementino; Pedro Enrique Dorlhiac Llacer; Anthony P Schwarer; Francois-Xavier Mahon; Delphine Rea; Susan Branford; Das Purkayastha; LaTonya Collins; Tomasz Szczudlo; Brian Leber
Journal:  Blood       Date:  2014-06-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.